Prostate Cancer, Version 2.2019, NCCN Clinical Practice Guidelines in Oncology
James L. Mohler 1 , Emmanuel S. Antonarakis 2 , Andrew J. Armstrong 3 , Anthony V. D’Amico 4 , Brian J. Davis 5 , Tanya Dorff 6 , James A. Eastham 7 , Charles A. Enke 8 , Thomas A. Farrington 9 , Celestia S. Higano 10 , Eric Mark Horwitz 11 , Michael Hurwitz 12 , Joseph E. Ippolito 13 , Christopher J. Kane 14 , Michael R. Kuettel 1 , Joshua M. Lang 15 , Jesse McKenney 16 , George Netto 17 , David F. Penson 18 , Elizabeth R. Plimack 11 , Julio M. Pow-Sang 19 , Thomas J. Pugh 20 , Sylvia Richey 21 , Mack Roach III 22 , Stan Rosenfeld 22 , Edward Schaeffer 23 , Ahmad Shabsigh 24 , Eric J. Small 22 , Daniel E. Spratt 25 , Sandy Srinivas 26 , Jonathan Tward 27 , Dorothy A. Shead 28 and Deborah A. Freedman-Cass 28
The NCCN Guidelines for Prostate Cancer include recommendations regarding diagnosis, risk stratification and workup, treatment options for localized disease, and management of recurrent and advanced disease for clinicians who treat patients with prostate cancer. The portions of the guidelines included herein focus on the roles of germline and somatic genetic testing, risk stratification with nomograms and tumor multigene molecular testing, androgen deprivation therapy, secondary hormonal therapy, chemotherapy, and immunotherapy in patients with prostate cancer.
Read Full Article Here: https://doi.org/10.6004/jnccn.2019.0023